O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
暂无分享,去创建一个
M. Ducreux | G. Abou-Alfa | L. Rimassa | E. Assenat | H. Pan | T. Zhang | J. Blanc | P. Merle | J. Edeline | A. Tran | Z. Li | W. Fang | J. Wu | Z. Ren | A. Cheng | S. Hu | P. Ross | C. Yen | V. Li | S. Chica-Duque